Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RELA | Q04206 | 4/20 | 0.43 |
| ▸ | FAAH | O00519 | 3/20 | 0.43 |
| ▸ | ADH1B | P00325 | 2/20 | 0.43 |
| ▸ | ADH1C | P00326 | 2/20 | 0.43 |
| ▸ | ADH1A | P07327 | 2/20 | 0.43 |
| ▸ | ADH7 | P40394 | 2/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | ADH4 | P08319 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL966697 | 0.98 | FAAH (0.46) | RELAFAAHADH1BADH1CADH1A | |
| SCHEMBL1751775 | 0.98 | FAAH (0.46) | RELAFAAHADH1BADH1CADH1A | |
| SCHEMBL4910687 | 0.98 | FAAH (0.46) | RELAFAAHADH1BADH1CADH1A | |
| SCHEMBL7522857 | 0.98 | FAAH (0.46) | RELAFAAHADH1BADH1CADH1A | |
| SCHEMBL8637402 | 0.98 | FAAH (0.46) | RELAFAAHADH1BADH1CADH1A | |
| SCHEMBL424438 | 0.93 | HPGD (0.43) | RELAFAAHADH1BADH1CADH1A | |
| SCHEMBL8520694 | 0.89 | RELA (0.37) | RELAFAAHADH1BADH1CADH1A | |
| SCHEMBL423937 | 0.83 | — | — | |
| SCHEMBL7446566 | 0.82 | FAAH (0.43) | RELAFAAHCA2MEN1ALDH1A1 | |
| SCHEMBL8560726 | 0.80 | FAAH (0.46) | RELAFAAHCA2MEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 263 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2581373-A1 | BENZO- OR PYRIDO-IMIDAZOLE DERIVATIVE | Fujita, Takashi (JP) | 2013-04-17 | — | — | EP | claimed |
| US-7767665-B2 | 3-[6-(4-oxo-4H-1,3-benzothiazin-2-yl)-2-pyridyl]propionic acid, having an excellent apoptosis inhibitory and Macrophage migration inhibitory factor (MIF) binding effects, used for preventing and/or treating cancers, AIDS, cardiovascular, neurodegeneartive, bone, kidney and liver disoders | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-08-03 | — | — | US | claimed |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-03-26 | — | — | US | claimed |
| EP-1608322-B1 | NAIL POLISH COMPOSITION AND METHOD OF MAKING SAME | DU PONT (US) | 2008-12-10 | — | — | EP | claimed |
| CN-1767806-A | Nail enamel composition and preparation method thereof | DU PONT (US) | 2006-05-03 | — | — | CN | claimed |
| EP-1608322-A1 | NAIL POLISH COMPOSITION AND METHOD OF MAKING SAME | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2005-12-28 | — | — | EP | claimed |
| US-20050227978-A1 | Fibrosis inhibitor | SUMITOMO PHARMACEUTICALS CO., LTD. (JP) | 2005-10-13 | — | — | US | claimed |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-02-10 | — | — | US | claimed |
| WO-2004087079-A1 | NAIL POLISH COMPOSITION AND METHOD OF MAKING SAME | E.I. DUPONT DE NEMOURS AND COMPANY (US) | 2004-10-14 | — | — | WO | claimed |
| US-20040191192-A1 | Nail polish composition and method of making same | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-09-30 | — | — | US | claimed |
| EP-0645134-A1 | Cosmetic composition containing as plastifiant an epoxylated oil | L'OREAL (FR) | 1995-03-29 | — | — | EP | claimed |
| US-5370866-A | Adhesion, bonding strength | L'OREAL (FR) | 1994-12-06 | — | — | US | claimed |
| US-5330750-A | Film former, solvent and crystalline calcium sulfate fibers | THE BOOTS COMPANY PLC. (GB) | 1994-07-19 | — | — | US | claimed |
| US-5028456-A | Unsaturated polyester, aromatic sulfonamide-aldehyde resin, repairing metal surfaces | OATEY COMPANY (US) | 1991-07-02 | — | — | US | claimed |
| US-4980414-A | CURABLE POLYESTER | OATEY COMPANY (US) | 1990-12-25 | — | — | US | claimed |
| US-4446869-A | Water absorbing trap to protect an infrared exhaled carbon dioxide apnea monitor of a patient's respiration | TRIMED, INC. (US) | 1984-05-08 | — | — | US | claimed |
| US-4283324-A | Nail enamel composition | AVON PRODUCTS, INC. (US) | 1981-08-11 | — | — | US | claimed |
| US-4134762-A | ELECTROPHOTOGRAPHY, HYDROPHOBIS RESIN | THE COMMONWEALTH OF AUSTRALIA (AU) | 1979-01-16 | — | — | US | claimed |
| US-4113650-A | CELLULOSE ACETATE BUTYRATE, ARYL SULFONAMIDE-FORMALDEHYDE RESIN | PFD/PENN COLOR, INC. (US) | 1978-09-12 | — | — | US | claimed |
| US-3959193-A | Utilization of cellulose acetate butyrate and aryl sulfonamide-formaldehyde resin containing dispersant | PFD/PENN COLOR, INC. (US) | 1976-05-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050227978-A1 | Fibrosis inhibitor | SMAD3, MMP1, SMAD2 | RELA 451/4885FAAH 2096/4885ADH1B 1960/4885 |
| US-20090082343-A1 | 1,3-BENZOTHIAZINONE DERIVATIVES AND USE THEREOF | MIF, MORF4L1, FOXM1 | RELA 69/4885FAAH 4017/4885ADH1B 1670/4885 |
| US-20050032786-A1 | 1, 3-benzothiazinone derivatives and use thereof | MIF, MORF4L1, FOXM1 | RELA 69/4885FAAH 4017/4885ADH1B 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.